Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG

Autores
Sanchez Sanchez, Maria Victoria; Ebensen, Thomas; Schulze, Kai; Cargnelutti, Diego Esteban; Scodeller, Eduardo; Guzmán, Carlos A.
Año de publicación
2023
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Current influenza vaccines target highly variable surface glycoproteins; thus, mismatchesbetween vaccine strains and circulating strains often diminish vaccine protection. For this reason,there is still a critical need to develop effective influenza vaccines able to protect also against thedrift and shift of different variants of influenza viruses. It has been demonstrated that influenzanucleoprotein (NP) is a strong candidate for a universal vaccine, which contributes to providingcross-protection in animal models. In this study, we developed an adjuvanted mucosal vaccine usingthe recombinant NP (rNP) and the TLR2/6 agonist S-[2,3-bispalmitoyiloxy-(2R)-propyl]-R-cysteinylamido-monomethoxyl-poly-ethylene-glycol (BPPcysMPEG). The vaccine efficacy was compared withthat observed following parenteral vaccination of mice with the same formulation. Mice vaccinatedwith 2 doses of rNP alone or co-administered with BPPcysMPEG by the intranasal (i.n.) route showedenhanced antigen-specific humoral and cellular responses. Moreover, NP-specific humoral immuneresponses, characterized by significant NP-specific IgG and IgG subclass titers in sera and NP-specificIgA titers in mucosal territories, were remarkably increased in mice vaccinated with the adjuvantedformulation as compared with those of the non-adjuvanted vaccination group. The addition ofBPPcysMPEG also improved NP-specific cellular responses in vaccinated mice, characterized byrobust lymphoproliferation and mixed Th1/Th2/Th17 immune profiles. Finally, it is notable thatthe immune responses elicited by the novel formulation administered by the i.n. route were able toconfer protection against the influenza H1N1 A/Puerto Rico/8/1934 virus.
Fil: Sanchez Sanchez, Maria Victoria. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
Fil: Ebensen, Thomas. Helmholtz Centre for Infection Research; Alemania
Fil: Schulze, Kai. Helmholtz Centre For Infection Research; Alemania
Fil: Cargnelutti, Diego Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
Fil: Scodeller, Eduardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
Fil: Guzmán, Carlos A.. Helmholtz Centre For Infection Research; Alemania
Materia
BPPcysMPEG
MALP-2
INFLUENZA
MUCOSA
ADJUVANT
VACCINE
NUCLEOPROTEIN
TLR2/6 AGONIST
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/230425
Acceder
id CONICETDig_3cf20830761c7ce3a940429dba031c71
oai_identifier_str oai:ri.conicet.gov.ar:11336/230425
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEGSanchez Sanchez, Maria VictoriaEbensen, ThomasSchulze, KaiCargnelutti, Diego EstebanScodeller, EduardoGuzmán, Carlos A.BPPcysMPEGMALP-2INFLUENZAMUCOSAADJUVANTVACCINENUCLEOPROTEINTLR2/6 AGONISThttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Current influenza vaccines target highly variable surface glycoproteins; thus, mismatchesbetween vaccine strains and circulating strains often diminish vaccine protection. For this reason,there is still a critical need to develop effective influenza vaccines able to protect also against thedrift and shift of different variants of influenza viruses. It has been demonstrated that influenzanucleoprotein (NP) is a strong candidate for a universal vaccine, which contributes to providingcross-protection in animal models. In this study, we developed an adjuvanted mucosal vaccine usingthe recombinant NP (rNP) and the TLR2/6 agonist S-[2,3-bispalmitoyiloxy-(2R)-propyl]-R-cysteinylamido-monomethoxyl-poly-ethylene-glycol (BPPcysMPEG). The vaccine efficacy was compared withthat observed following parenteral vaccination of mice with the same formulation. Mice vaccinatedwith 2 doses of rNP alone or co-administered with BPPcysMPEG by the intranasal (i.n.) route showedenhanced antigen-specific humoral and cellular responses. Moreover, NP-specific humoral immuneresponses, characterized by significant NP-specific IgG and IgG subclass titers in sera and NP-specificIgA titers in mucosal territories, were remarkably increased in mice vaccinated with the adjuvantedformulation as compared with those of the non-adjuvanted vaccination group. The addition ofBPPcysMPEG also improved NP-specific cellular responses in vaccinated mice, characterized byrobust lymphoproliferation and mixed Th1/Th2/Th17 immune profiles. Finally, it is notable thatthe immune responses elicited by the novel formulation administered by the i.n. route were able toconfer protection against the influenza H1N1 A/Puerto Rico/8/1934 virus.Fil: Sanchez Sanchez, Maria Victoria. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Ebensen, Thomas. Helmholtz Centre for Infection Research; AlemaniaFil: Schulze, Kai. Helmholtz Centre For Infection Research; AlemaniaFil: Cargnelutti, Diego Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Scodeller, Eduardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Guzmán, Carlos A.. Helmholtz Centre For Infection Research; AlemaniaMDPI2023-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/230425Sanchez Sanchez, Maria Victoria; Ebensen, Thomas; Schulze, Kai; Cargnelutti, Diego Esteban; Scodeller, Eduardo; et al.; Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG; MDPI; Pharmaceutics; 15; 3; 3-2023; 1-221999-4923CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/1999-4923/15/3/912info:eu-repo/semantics/altIdentifier/doi/10.3390/pharmaceutics15030912info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:11:43Zoai:ri.conicet.gov.ar:11336/230425instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:11:43.555CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG
title Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG
spellingShingle Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG
Sanchez Sanchez, Maria Victoria
BPPcysMPEG
MALP-2
INFLUENZA
MUCOSA
ADJUVANT
VACCINE
NUCLEOPROTEIN
TLR2/6 AGONIST
title_short Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG
title_full Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG
title_fullStr Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG
title_full_unstemmed Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG
title_sort Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG
dc.creator.none.fl_str_mv Sanchez Sanchez, Maria Victoria
Ebensen, Thomas
Schulze, Kai
Cargnelutti, Diego Esteban
Scodeller, Eduardo
Guzmán, Carlos A.
author Sanchez Sanchez, Maria Victoria
author_facet Sanchez Sanchez, Maria Victoria
Ebensen, Thomas
Schulze, Kai
Cargnelutti, Diego Esteban
Scodeller, Eduardo
Guzmán, Carlos A.
author_role author
author2 Ebensen, Thomas
Schulze, Kai
Cargnelutti, Diego Esteban
Scodeller, Eduardo
Guzmán, Carlos A.
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv BPPcysMPEG
MALP-2
INFLUENZA
MUCOSA
ADJUVANT
VACCINE
NUCLEOPROTEIN
TLR2/6 AGONIST
topic BPPcysMPEG
MALP-2
INFLUENZA
MUCOSA
ADJUVANT
VACCINE
NUCLEOPROTEIN
TLR2/6 AGONIST
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Current influenza vaccines target highly variable surface glycoproteins; thus, mismatchesbetween vaccine strains and circulating strains often diminish vaccine protection. For this reason,there is still a critical need to develop effective influenza vaccines able to protect also against thedrift and shift of different variants of influenza viruses. It has been demonstrated that influenzanucleoprotein (NP) is a strong candidate for a universal vaccine, which contributes to providingcross-protection in animal models. In this study, we developed an adjuvanted mucosal vaccine usingthe recombinant NP (rNP) and the TLR2/6 agonist S-[2,3-bispalmitoyiloxy-(2R)-propyl]-R-cysteinylamido-monomethoxyl-poly-ethylene-glycol (BPPcysMPEG). The vaccine efficacy was compared withthat observed following parenteral vaccination of mice with the same formulation. Mice vaccinatedwith 2 doses of rNP alone or co-administered with BPPcysMPEG by the intranasal (i.n.) route showedenhanced antigen-specific humoral and cellular responses. Moreover, NP-specific humoral immuneresponses, characterized by significant NP-specific IgG and IgG subclass titers in sera and NP-specificIgA titers in mucosal territories, were remarkably increased in mice vaccinated with the adjuvantedformulation as compared with those of the non-adjuvanted vaccination group. The addition ofBPPcysMPEG also improved NP-specific cellular responses in vaccinated mice, characterized byrobust lymphoproliferation and mixed Th1/Th2/Th17 immune profiles. Finally, it is notable thatthe immune responses elicited by the novel formulation administered by the i.n. route were able toconfer protection against the influenza H1N1 A/Puerto Rico/8/1934 virus.
Fil: Sanchez Sanchez, Maria Victoria. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
Fil: Ebensen, Thomas. Helmholtz Centre for Infection Research; Alemania
Fil: Schulze, Kai. Helmholtz Centre For Infection Research; Alemania
Fil: Cargnelutti, Diego Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
Fil: Scodeller, Eduardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
Fil: Guzmán, Carlos A.. Helmholtz Centre For Infection Research; Alemania
description Current influenza vaccines target highly variable surface glycoproteins; thus, mismatchesbetween vaccine strains and circulating strains often diminish vaccine protection. For this reason,there is still a critical need to develop effective influenza vaccines able to protect also against thedrift and shift of different variants of influenza viruses. It has been demonstrated that influenzanucleoprotein (NP) is a strong candidate for a universal vaccine, which contributes to providingcross-protection in animal models. In this study, we developed an adjuvanted mucosal vaccine usingthe recombinant NP (rNP) and the TLR2/6 agonist S-[2,3-bispalmitoyiloxy-(2R)-propyl]-R-cysteinylamido-monomethoxyl-poly-ethylene-glycol (BPPcysMPEG). The vaccine efficacy was compared withthat observed following parenteral vaccination of mice with the same formulation. Mice vaccinatedwith 2 doses of rNP alone or co-administered with BPPcysMPEG by the intranasal (i.n.) route showedenhanced antigen-specific humoral and cellular responses. Moreover, NP-specific humoral immuneresponses, characterized by significant NP-specific IgG and IgG subclass titers in sera and NP-specificIgA titers in mucosal territories, were remarkably increased in mice vaccinated with the adjuvantedformulation as compared with those of the non-adjuvanted vaccination group. The addition ofBPPcysMPEG also improved NP-specific cellular responses in vaccinated mice, characterized byrobust lymphoproliferation and mixed Th1/Th2/Th17 immune profiles. Finally, it is notable thatthe immune responses elicited by the novel formulation administered by the i.n. route were able toconfer protection against the influenza H1N1 A/Puerto Rico/8/1934 virus.
publishDate 2023
dc.date.none.fl_str_mv 2023-03
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/230425
Sanchez Sanchez, Maria Victoria; Ebensen, Thomas; Schulze, Kai; Cargnelutti, Diego Esteban; Scodeller, Eduardo; et al.; Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG; MDPI; Pharmaceutics; 15; 3; 3-2023; 1-22
1999-4923
CONICET Digital
CONICET
url http://hdl.handle.net/11336/230425
identifier_str_mv Sanchez Sanchez, Maria Victoria; Ebensen, Thomas; Schulze, Kai; Cargnelutti, Diego Esteban; Scodeller, Eduardo; et al.; Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG; MDPI; Pharmaceutics; 15; 3; 3-2023; 1-22
1999-4923
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/1999-4923/15/3/912
info:eu-repo/semantics/altIdentifier/doi/10.3390/pharmaceutics15030912
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844614018462908416
score 13.070432

Publicaciones similares